# A Phase II Study of CP-4055 as Second Line Therapy in Patients With Advanced Colorectal Cancer

> **NCT00498407** · PHASE2 · COMPLETED · sponsor: **Clavis Pharma** · enrollment: 16 (actual)

## Conditions studied

- Advanced Colorectal Cancer
- Colorectal Cancer

## Interventions

- **DRUG:** CP-4055

## Key facts

- **NCT ID:** NCT00498407
- **Lead sponsor:** Clavis Pharma
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-05
- **Primary completion:** 2008-12
- **Final completion:** 2008-12
- **Target enrollment:** 16 (ACTUAL)
- **Last updated:** 2009-06-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00498407

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00498407, "A Phase II Study of CP-4055 as Second Line Therapy in Patients With Advanced Colorectal Cancer". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT00498407. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*